

Nikolai A Podoltsev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4147182/publications.pdf>

Version: 2024-02-01

121
papers

3,364
citations

236925

25
h-index

161849

54
g-index

121
all docs

121
docs citations

121
times ranked

4106
citing authors

#	ARTICLE	IF	CITATIONS
1	Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. <i>European Journal of Rheumatology</i> , 2023, 9, 215-216.	0.6	0
2	Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. <i>Annals of Hematology</i> , 2022, 101, 1145-1147.	1.8	4
3	Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. <i>Blood Advances</i> , 2022, 6, 376-385.	5.2	5
4	Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	1.4	55
5	Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1766-1770.	1.4	4
6	Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. <i>Blood Advances</i> , 2022, 6, 3339-3342.	5.2	5
7	European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. <i>HemaSphere</i> , 2022, 6, e721.	2.7	9
8	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	23
9	Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. <i>Leukemia Research</i> , 2022, 119, 106903.	0.8	0
10	Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	4.1	16
11	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1195-1202.	1.3	5
12	Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. <i>Blood Reviews</i> , 2021, 47, 100773.	5.7	63
13	Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. <i>Leukemia</i> , 2021, 35, 1643-1660.	7.2	29
14	Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 92-99.	1.6	13
15	Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 994-1002.	5.2	18
16	A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule 1 (CLL1) in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E175-E179.	4.1	3
17	Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-10.	1.3	0
18	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 177-189.	2.2	14
20	Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e483-e487.	0.4	1
21	Emerging agents and regimens for polycythemia vera and essential thrombocythemia. <i>Biomarker Research</i> , 2021, 9, 40.	6.8	7
22	Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e551-e558.	0.4	3
23	Laboratory evaluation and prognostication among adults and children with <i>CEBPA</i> mutant acute myeloid leukemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 86-95.	1.3	6
24	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2021, 62, 3394-3401.	1.3	17
25	Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation—A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 997.e1-997.e11.	1.2	20
26	Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. <i>Leukemia Research</i> , 2021, 109, 106629.	0.8	3
27	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 873.e1-873.e13.	1.2	9
28	Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. <i>Current Opinion in Hematology</i> , 2021, 28, 110-121.	2.5	3
29	A case of acute myeloid leukemia with unusual germline <i>CEBPA</i> mutation: lessons learned about mutation detection, location, and penetrance. <i>Leukemia and Lymphoma</i> , 2021, 62, 1251-1254.	1.3	6
30	Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110434.	2.5	3
31	European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database. <i>Blood</i> , 2021, 138, 240-240.	1.4	3
32	Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. <i>Blood</i> , 2021, 138, 4092-4092.	1.4	0
33	Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152. <i>Blood</i> , 2021, 138, 3407-3407.	1.4	5
34	Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics. <i>Blood</i> , 2021, 138, 2583-2583.	1.4	1
35	Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis. <i>Blood</i> , 2021, 138, 182-182.	1.4	0
36	Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. <i>Leukemia and Lymphoma</i> , 2020, 61, 397-408.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study. <i>International Journal of Cancer</i> , 2020, 147, 948-957.	5.1	9
38	Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. <i>Leukemia and Lymphoma</i> , 2020, 61, 1178-1187.	1.3	15
39	Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2343-2350.	2.5	1
40	Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. <i>Leukemia and Lymphoma</i> , 2020, 61, 2180-2190.	1.3	24
41	Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e712-e723.	0.4	12
42	Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. <i>Blood</i> , 2020, 135, 1696-1703.	1.4	54
43	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	5.2	29
44	Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. <i>Blood Advances</i> , 2020, 4, 2192-2201.	5.2	68
45	Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2020, 13, 447-460.	2.2	2
46	Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption. <i>International Journal of Cancer</i> , 2020, 146, 3523-3523.	5.1	1
47	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	7.2	54
48	Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S101-S102.	2.0	2
49	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
50	Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia. <i>Leukemia Research</i> , 2020, 90, 106315.	0.8	3
51	Isolated trisomy 11 in patients with acute myeloid leukemia " is the prognosis not as grim as previously thought?*. <i>Leukemia and Lymphoma</i> , 2020, 61, 2254-2257.	1.3	1
52	Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. <i>Blood Advances</i> , 2020, 4, 1615-1623.	5.2	32
53	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.4	12
54	Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. <i>Blood Reviews</i> , 2020, 42, 100706.	5.7	54

#	ARTICLE	IF	CITATIONS
55	Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. <i>Blood</i> , 2020, 136, 22-23.	1.4	6
56	A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results. <i>Blood</i> , 2020, 136, 16-17.	1.4	19
57	Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 29-29.	1.4	2
58	Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 2245-2253.	5.2	36
59	Patterns of Care and Outcomes Among Older Patients with Myelofibrosis: A Population-Based Study. <i>Blood</i> , 2020, 136, 21-22.	1.4	1
60	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 246-249.	1.3	0
61	Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. <i>Cancer</i> , 2019, 125, 4084-4095.	4.1	10
62	Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. <i>Cancer</i> , 2019, 125, 4241-4251.	4.1	28
63	Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	27.0	796
64	Acute myeloid leukemia presenting as bilateral adrenal hemorrhage. <i>Annals of Hematology</i> , 2019, 98, 2421-2423.	1.8	2
65	A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. <i>Nature Communications</i> , 2019, 10, 366.	12.8	60
66	RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 3181-3187.	1.3	9
67	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. <i>Lancet Haematology</i> , 2019, 6, e317-e327.	4.6	71
68	What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1169-1173.	1.8	6
69	Trends and factors affecting the US adult hematology workforce: a mixed methods study. <i>Blood Advances</i> , 2019, 3, 3550-3561.	5.2	18
70	Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database. <i>Blood</i> , 2019, 134, 2949-2949.	1.4	2
71	Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab. <i>Blood</i> , 2019, 134, 3809-3809.	1.4	3
72	Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). <i>Blood</i> , 2019, 134, 4748-4748.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration. <i>Blood</i> , 2019, 134, 2957-2957.	1.4	3
74	Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 211-219.	4.9	6
75	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
76	Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. <i>Blood</i> , 2018, 131, 1486-1489.	1.4	17
77	Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. <i>Blood</i> , 2018, 131, 818-821.	1.4	45
78	The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. <i>Blood Advances</i> , 2018, 2, 2681-2690.	5.2	13
79	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 1765-1772.	5.2	100
80	A rare case of visceral leishmaniasis in an immunocompetent traveler returning to the United States from Europe. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006727.	3.0	7
81	Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. <i>Cancer</i> , 2018, 124, 4211-4220.	4.1	9
82	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	5.2	114
83	Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. <i>Blood Cancer Journal</i> , 2018, 8, 55.	6.2	26
84	Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. <i>Annals of Hematology</i> , 2018, 97, 2333-2343.	1.8	6
85	Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2018, 132, 231-231.	1.4	4
86	Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 564-564.	1.4	41
87	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 1428-1428.	1.4	1
88	Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. <i>Blood</i> , 2018, 132, 3538-3538.	1.4	0
89	Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. <i>Blood</i> , 2018, 132, 3580-3580.	1.4	2
90	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 4040-4040.	1.4	4

#	ARTICLE	IF	CITATIONS
91	Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study. <i>Cancer</i> , 2017, 123, 3754-3762.	4.1	18
92	NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1193-1207.	4.9	119
93	Guadecitabine (SGI-110) in treatment-naïve patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. <i>Lancet Oncology</i> , 2017, 18, 1317-1326.	10.7	148
94	Selecting initial treatment of acute myeloid leukaemia in older adults. <i>Blood Reviews</i> , 2017, 31, 43-62.	5.7	74
95	Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. <i>Journal of Clinical Oncology</i> , 2017, 35, 3417-3424.	1.6	61
96	Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2017, 130, 722-722.	1.4	84
97	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. <i>PLoS ONE</i> , 2017, 12, e0184747.	2.5	9
98	Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States. <i>Blood</i> , 2017, 130, 675-675.	1.4	0
99	Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 175, 829-840.	2.5	59
100	Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2016, 95, 1895-1898.	1.8	2
101	A Patient With Pancytopenia, Intractable Epistaxis, and Metastatic Prostate Cancer: How Correct Diagnosis of Primary Hyperfibrinolysis Helps to Stop the Bleeding. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e545-e548.	1.9	6
102	The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions. <i>Blood Reviews</i> , 2016, 30, 1-10.	5.7	32
103	Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 646-651.	0.9	5
104	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. <i>Blood</i> , 2016, 128, 1063-1063.	1.4	5
105	Factors Influencing Hematology Career Choice in Hematology and Oncology Fellows at a Major Academic Institution. <i>Blood</i> , 2016, 128, 3538-3538.	1.4	3
106	Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. <i>Blood</i> , 2016, 128, 394-394.	1.4	0
107	Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 766-770.e4.	0.4	13
108	Efficient Engraftment and Disease Replication of Myelodysplastic Syndromes Using a Novel Humanized Mice Model. <i>Blood</i> , 2015, 126, 4100-4100.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). <i>Blood</i> , 2015, 126, 3285-3285.	1.4	1
110	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. <i>Blood</i> , 2015, 126, 1138-1138.	1.4	4
111	Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Blood</i> , 2015, 126, 4455-4455.	1.4	0
112	Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. <i>Oxford Medical Case Reports</i> , 2014, 2014, 138-140.	0.4	7
113	Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. <i>Nature Genetics</i> , 2014, 46, 1135-1139.	21.4	417
114	Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 303-307.	2.3	15
115	First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2014, 124, 529-529.	1.4	4
116	Chemoimmunotherapy and Withdrawal of Immunosuppression for Monomorphic Posttransplant Lymphoproliferative Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 716-720.	0.4	6
117	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 497-497.	1.4	23
118	Myocardial infarction in a young adult undergoing induction treatment for acute lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 675-7.	0.3	0
119	Incidence and Outcomes for Low Risk Myelodysplastic Syndrome: A Surveillance, Epidemiology and End Results (SEER) Study. <i>Blood</i> , 2012, 120, 4944-4944.	1.4	0
120	Post-Transplantation Lymphoproliferative Disorders (PTLD) Management in Solid Organ Transplantation (SOT) Recipients. <i>Blood</i> , 2011, 118, 4941-4941.	1.4	0
121	Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. <i>Leukemia</i> , 0, , .	7.2	4